CD8A and triple-negative breast carcinoma: In triple-negative breast cancer and NSCLC, higher cytotoxic T cells (CD8+ T cells) demonstrate higher rates of overall response to ICBs, along with improved progression-free and overall survivals (PFS and OS, respectively) compared with those with lower CD8+ T cells [15,16].